868694-44-4

Usage

Uses

tert-Butyl [(S)-1-amino-3-(4-iodophenyl)-1-oxopropan-2-yl]carbamate can be used to prepare cathepsin C inhibitors.

Upstream product

• 1991-81-7 4-iodo-L-phenylalanine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 103882-09-3 N-Boc-4-I-Phe-OH 

Downstream Products

• 97964-72-2 (S)-2-amino-3-(4-iodophenyl)propionamamide 
• 1428666-13-0 (1R,3S,4S)-tert-butyl 3-((S)-1-cyano-2-(4-iodophenyl)ethylcarbamoyl)-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 1428666-14-1 (1R, 3S, 4S)-tert-butyl 3-((S)-1-amino-3-(4-iodophenyl)-1-oxopropan-2-ylcarbamoyl)-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 1428666-93-6 C₂₃H₂₉N₃O₃ 
• 1428666-95-8 C₂₃H₃₁N₃O₃ 
• 1428666-97-0 C₂₆H₃₉N₅O₄ 
• 1428666-37-8 C₂₄H₃₁N₃O₃ 
• 1159630-53-1 (S)-2-amino-3-(4-iodophenyl)propanenitrile 
• 1352152-42-1 (S)-tert-butyl 1-(1-amino-3-(4-(1-(difluoromethyl)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-1-oxopropan-2-ylcarbamoyl)cyclohexylcarbamate 
• 1352152-36-3 (S)-1-amino-N-(1-cyano-2-(4-(2-(2-(dimethylamino)ethyl)-1-oxoisoindolin-5-yl)phenyl)ethyl)cyclohexanecarboxamide 
• 1352152-38-5 (S)-tert-butyl 1-(1-amino-3-(4-(2-(2-(dimethylamino)ethyl)-1-oxoisoindolin-5-yl)phenyl)-1-oxopropan-2-ylcarbamoyl)cyclohexylcarbamate 
• 1352152-32-9 1-amino-N-{(1S)-1-cyano-2-[4-(2-methyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl)phenyl]ethyl}cyclohexanecarboxamide 
• 1352152-34-1 tert-butyl [1-({(1S)-1-cyano-2-[4-(2-methyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl)phenyl]ethyl}carbamoyl)cyclohexyl]carbamate 
• 1352152-29-4 (S)-1-amino-N-(1-cyano-2-(4-(1-ethyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)cyclohexanecarboxamide 

Relevant academic research and scientific papers

Development of potent and selective Cathepsin C inhibitors free of aortic binding liability by application of a conformational restriction strategy

Cathepsin C plays a key role in the activation of several degradative enzymes linked to tissue destruction in chronic inflammatory and autoimmune diseases. Therefore, Cathepsin C inhibitors could potentially be effective therapeutics for the treatment of diseases such as chronic obstructive pulmonary disease (COPD) or acute respiratory distress syndrome (ARDS). In our efforts towards the development of a novel series of Cathepsin C inhibitors, we started working around AZD5248 (1), an α-amino acid based scaffold having potential liability of aortic binding. A novel series of amidoacetonitrile based Cathepsin C inhibitors were developed by the application of a conformational restriction strategy on 1. In particular, this work led to the development of a potent and selective Cathepsin C inhibitor 3p, free of aortic binding liability.

Cathepsin C inhibitors: Property optimization and identification of a clinical candidate

A lead generation and optimization program delivered the highly selective and potent CatC inhibitor 10 as an in vivo tool compound and potential development candidate. Structural studies were undertaken to generate SAR understanding.

SUBSTITUTED BICYCLIC 1-CARBOXYLIC-ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C

This invention relates to bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and their use in methods of treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

SUBSTITUTED 2-AZA-BICYCLO[2.2.2]OCTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C

This invention relates to 2-Aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

SUBSTITUTED 2-AZA-BICYCLO[2.2.2]OCTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C

This invention relates to 2-Aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. asthma and allergic diseases, gastrointestinal inflammatory diseases, eosinophilic diseases, chronic obstructive pulmonary disease, infection by pathogenic microbes, rheumatoid arthritis or atherosclerosis.

SUBSTITUTED BICYCLIC 1-CARBOXYLIC-ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C

This invention relates to bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL] -2-AZABICYCLO [2.2.1] HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C

This invention relates to N-1-cyano-2-(phenyl)ethyl)-2-azabicyclo[2.2.1]heptane-3-carboxamides of formula I, and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of respiratory diseases.

SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL] -2-AZABICYCLO [2.2.1] HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C

Disclosed are N-1-cyano-2-(phenyl)ethyl)-2-azabicyclo[2.2.1]heptane-3-carboxamides of formula I and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of respiratory diseases.

SUBSTITUTED N-[1-CYANO-2-(PHENYL)ETHYL] 1-AMINOCYCLOALK-1-YLCARBOXAMIDE COMPOUNDS - 760

The present invention provides compounds of formula (I) in which, n, R1, R2 and Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.

SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750

The present invention provides compounds of formula (I), in which y, m, n, R1, R2 and Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.